Jonathan Curtain appointed CFO
25/01/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230125:nRSY7533Na&default-theme=true
RNS Number : 7533N Ergomed plc 25 January 2023
Board Change
Richard Barfield to retire as Chief Financial Officer
to be succeeded by Jonathan Curtain
Guildford, UK - 25 January 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces that Richard Barfield, Chief
Financial Officer, has informed the Board of his intention to retire on 3
February 2023, following which he will cease to be a Director. The company is
pleased to announce that Jonathan Curtain, Deputy Chief Financial Officer,
will be appointed as Chief Financial Officer and as an Executive Director of
the Board of Ergomed with effect from 3 February 2023.
Jonathan joined Ergomed in November 2022, bringing with him extensive life
sciences industry experience, having spent 13 years with ICON plc, a leading
global CRO business listed on NASDAQ with a market capitalisation of $19
billion. Most recently, he was the Senior Vice President of Corporate and
Commercial Finance, where he had a broad range of responsibilities including
financial reporting, acquisitions and post-acquisition integration, debt and
equity fundraising, treasury, commercial finance and overall financial
management. During his time with ICON, he also led the Investor Relations
function and played a key role in transactions worth over $13.5
billion including most recently the $12 billion acquisition by ICON of PRA
Health Sciences Inc. Jonathan is a Fellow of the Institute of Chartered
Accountants with over 20 years' experience since receiving his ACA
qualification at KPMG.
Richard Barfield joined Ergomed in May 2019 as Chief Financial Officer. Having
reached the age of 65 last July, he has decided to retire and looks forward to
spending more time with his family.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, commented: "On behalf
of the entire team at Ergomed, I would like to express my sincere thanks to
Richard for his service to the business since joining as CFO in 2019. He has
made a significant contribution to establishing the platform for sustained
growth that we now have in place. I am also very pleased to announce
Jonathan's appointment as CFO and to the Board. Our belief in his ability to
contribute further to Ergomed's success has been further strengthened during
his time as Deputy CFO. I wish Richard well for his retirement and I am
confident that in Jonathan we have a very strong successor who will continue
to deliver on our global strategy."
Additional Disclosures
The following information regarding the appointment of Jonathan Andrew
Curtain, aged 46, is disclosed under Schedule 2(g) of the AIM Rules for
Companies:
Current directorships/partnerships: Past directorships/partnerships (within the last five years):
None. Icon Global Treasury Unlimited Company
Recherche Clinique Icon (Canada) Inc (also known as Icon Clinical Research
(Canada) Inc)
Jonathan Curtain does not hold any legal or beneficial direct or indirect
interest in the securities of the Company.
There is no further information required to be disclosed in respect of the
above appointment pursuant to Rule 17 or Schedule 2 (g) of the AIM Rules for
Companies.
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Jonathan Curtain (Deputy Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets & Strategy)
Numis (Nominated Adviser and Joint Broker) Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Euan Brown (Nominated Adviser)
James Black (Broker)
Peel Hunt (Joint Broker) Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher
Golden
Consilium Strategic Communications - for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal / Maya Bennison ergomed@consilium-comms.com (mailto:ergomed@consilium-comms.com)
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCUSSAROVUAUUR